Skip to main content
Journal cover image

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.

Publication ,  Journal Article
Rizzieri, DA; Sand, GJ; McGaughey, D; Moore, JO; DeCastro, C; Chao, NJ; Vredenburgh, JJ; Gasparetto, C; Long, GD; Anderson, E; Foster, T ...
Published in: Cancer
June 1, 2004

BACKGROUND: Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high-dose taxanes have not been reported to be very effective for the treatment of lymphoma, different delivery rates may allow for different mechanisms of action to be manifest and result in a different toxicity profile and response rate. The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL. METHODS: Adults age > 18 years with refractory or recurrent, aggressive NHL who were not considered curable with standard high-dose therapy received paclitaxel at a dose of 80 mg/m2 weekly for 5 weeks for 2 cycles. RESULTS: Thirty-four patients with refractory NHL and 4 patients with recurrent disease were treated. Approximately 45% of the patients had achieved a prior disease remission. The median number of prior regimens received was 3, 74% of the patients had an International Prognostic Index of > or = 3 at the time of study entry, and 29% had failed high-dose therapy with autologous hematopoietic support. Only one patient encountered severe toxicity (sepsis). Myelosuppression was reported to occur in approximately 20% of patients. A total of 10 patients (26%) achieved a complete disease response and 4 patients (11%) achieved a partial response. CONCLUSIONS: In the current study, low-dose, weekly paclitaxel therapy was found to provide a well tolerated and less toxic approach to the treatment of refractory NHL, with encouraging responses noted in heavily pretreated patients. However, evaluation in patients with an earlier stage of disease is warranted.

Duke Scholars

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

June 1, 2004

Volume

100

Issue

11

Start / End Page

2408 / 2414

Location

United States

Related Subject Headings

  • Salvage Therapy
  • Remission Induction
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Microcirculation
  • Maximum Tolerated Dose
  • Male
  • Lymphoma, Non-Hodgkin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rizzieri, D. A., Sand, G. J., McGaughey, D., Moore, J. O., DeCastro, C., Chao, N. J., … Gockerman, J. P. (2004). Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer, 100(11), 2408–2414. https://doi.org/10.1002/cncr.20245
Rizzieri, David A., Gregory J. Sand, Dean McGaughey, Joseph O. Moore, Carlos DeCastro, Nelson J. Chao, James J. Vredenburgh, et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.Cancer 100, no. 11 (June 1, 2004): 2408–14. https://doi.org/10.1002/cncr.20245.
Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, et al. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer. 2004 Jun 1;100(11):2408–14.
Rizzieri, David A., et al. “Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.Cancer, vol. 100, no. 11, June 2004, pp. 2408–14. Pubmed, doi:10.1002/cncr.20245.
Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, Vredenburgh JJ, Gasparetto C, Long GD, Anderson E, Foster T, Toaso B, Adams D, Niedzwiecki D, Gockerman JP. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer. 2004 Jun 1;100(11):2408–2414.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

June 1, 2004

Volume

100

Issue

11

Start / End Page

2408 / 2414

Location

United States

Related Subject Headings

  • Salvage Therapy
  • Remission Induction
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Microcirculation
  • Maximum Tolerated Dose
  • Male
  • Lymphoma, Non-Hodgkin